Cannara Biotech Inc.
LOVE.V
TSX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 76.57M | 72.88M | 67.78M | 63.93M | 60.02M |
| Total Other Revenue | 248.10K | 67.80K | 119.00K | 119.00K | 119.00K |
| Total Revenue | 76.81M | 72.95M | 67.85M | 64.00M | 60.08M |
| Cost of Revenue | 43.08M | 40.51M | 39.47M | 40.82M | 38.23M |
| Gross Profit | 33.73M | 32.44M | 28.38M | 23.18M | 21.85M |
| SG&A Expenses | 16.61M | 15.69M | 15.19M | 15.39M | 14.45M |
| Depreciation & Amortization | 1.13M | 925.20K | 942.00K | 913.90K | 1.01M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.33M | 57.68M | 56.28M | 57.92M | 54.52M |
| Operating Income | 15.49M | 15.27M | 11.57M | 6.08M | 5.57M |
| Income Before Tax | 12.94M | 12.40M | 9.77M | 3.90M | 3.24M |
| Income Tax Expenses | 3.59M | 1.26M | 90.60K | -898.00K | -1.43M |
| Earnings from Continuing Operations | 9.35 | 11.14 | 9.68 | 4.80 | 4.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.35M | 11.14M | 9.68M | 4.80M | 4.66M |
| EBIT | 15.49M | 15.27M | 11.57M | 6.08M | 5.57M |
| EBITDA | 20.08M | 19.54M | 16.04M | 10.49M | 10.05M |
| EPS Basic | 0.10 | 0.12 | 0.11 | 0.05 | 0.05 |
| Normalized Basic EPS | 0.09 | 0.08 | 0.06 | 0.01 | 0.01 |
| EPS Diluted | 0.09 | 0.12 | 0.10 | 0.05 | 0.04 |
| Normalized Diluted EPS | 0.08 | 0.08 | 0.05 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 363.45M | 362.03M | 360.62M | 360.08M | 360.28M |
| Average Diluted Shares Outstanding | 369.82M | 367.96M | 366.88M | 364.64M | 364.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |